IDSA 2020 Guidelines Could Inform Current Practice Standards for Treatment of Antimicrobial Resistant Gram-Negative Bacterial Infections
In part 2 of the discussion, Lodise said the decision of which drugs to use for various infections is very nuanced, but the new guidance document utilized the best available evidence.
In an interview with Pharmacy Times, Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections. The guidelines were reviewed in a session at the American Society of Health-System Pharmacists titled "Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline."
In part 2 of the discussion, Lodise said the decision of which drugs to use for various infections is very nuanced, but the new guidance document utilized the best available evidence. In the interview, Lodise also discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.
